# OnCo record paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017" ;
  schema:name "SARC028: pembrolizumab in advanced soft tissue and bone sarcoma"@en ;
  schema:description "Pembrolizumab had little effect in most sarcomas, but it shrank tumours in about 40 percent of patients with undifferentiated pleomorphic sarcoma and some with dedifferentiated liposarcoma, singling out these subtypes for immunotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30624-1>, <https://pubmed.ncbi.nlm.nih.gov/28988646/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(17)30624-1> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Tawbi HA, Burgess M, Bolejack V, et al." ;
  onco:cancers <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/sarc028/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .